Profusa, Inc. (PFSA)
NASDAQ: PFSA · Real-Time Price · USD
13.57
-13.91 (-50.62%)
At close: Aug 19, 2026, 4:00 PM EDT
13.24
-0.33 (-2.43%)
Pre-market: Aug 20, 2026, 8:27 AM EDT
Profusa Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
632.39K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 100.00K | 55.00K | 122.22% |
| Dec 31, 2023 | 45.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 742.00K | -3.20M | -81.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivos Therapeutics | 20.90M |
| Nuwellis | 9.01M |
| Beyond Air | 7.69M |
| INVO Fertility | 7.53M |
| VolitionRx | 2.46M |
| ENvue Medical | 1.93M |
| Catheter Precision | 1.92M |
PFSA News
- 3 days ago - Profusa announces 1-for-4 reverse stock split - TheFly
- 3 days ago - Profusa Inc trading halted, news pending - TheFly
- 7 days ago - Profusa Announces 1-for-4 Reverse Stock Split - GlobeNewsWire
- 19 days ago - Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs - GlobeNewsWire
- 24 days ago - Profusa to acquire diagnostics company, appoints Jack Stover CEO - TheFly
- 24 days ago - Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company - GlobeNewsWire
- 6 weeks ago - Profusa Inc trading halted, news pending - TheFly
- 6 weeks ago - Profusa announces 1-for-25 reverse stock split - TheFly